tbuckley/cabot-search huggingface dataset:
Correction
Journal: BMJ (1955)

Treatment of Disseminated Sclerosis with Histamine and Curare Q.-I would be grateful if I could have some information about the treatment of disseminated sclerosis with histamine and curare.Have these drugs a place in rational therapy ?A.-Daily intravenous injections of histamine diphosphate were used in the treatment of disseminated sclerosis by Horton and his colleagues' in 1944.There was improve- ment in some patients especially in the early stages of the disease, and this was attributed to vasodilatation, but the difficulty of evaluating the results on account of the possi- bility of spontaneous remissions was realized.Curare has been used in an effort to reduce spasticity in cases of spastic paraplegia whether due to disseminated sclerosis or other disorders of the spinal cord.The results have on the whole been disappointing, and toxic side effects are fairly frequent.2A carefully controlled study' of the use of D-tubocurarine in oil and wax given by intramuscular injection in the treat- ment of spasticity resulting from spinal cord injuries indi- cated that no beneficial results were obtained.
Good intentions do pave road to safe harbors, but taking contravention avenues remains risky
Authors: T. Randall
Journal: JAMA (1991)

NEARLY FOUR MONTHS have passed since Richard Kusserow, inspector general for the US Department of Health and Human Services (DHHS), issued safe harbor regulations to help "self-referring" physicians steer clear of federal antikickback investigations. Additional safe harbors, plus interpretive rules, are expected early in 1992. But when these original regulations were issued, few physicians who had invested in health care facilities to which they refer patients found themselves within these safe harbors. Most of them, instead, had to decide whether to restructure, divest, or remain vulnerable to potential criminal and civil sanctions under the 1977 Medicare and Medicaid antikickback statute. <h3>Critical 40%</h3> To fall within safe harbors, no more than 40% of a facility may be owned by those in a position to refer patients to that facility. And referrals from owners should contribute no more than 40% of the facility's business. Under these new regulations, a hospital is also
Clinical relevance of TNM staging system according to breast cancer subtypes
Authors: Y.H. Park, S.J. Lee, E.Y. Cho, Y. La. Choi, J.E. Lee, S.J. Nam, J.-H. Yang, J.H. Shin, E.Y. Ko, B.-K. Han, J.S. Ahn, Y.-H. Im
Journal: Annals of Oncology (2019)

Ann Oncol 2011; 22(11): 1554–1560 (doi: 10.1093/annonc/mdq617) In the original article, Figure 4B was identical to Figure 4A. This has now been corrected online and appears below. Clinical relevance of TNM staging system according to breast cancer subtypesAnnals of OncologyVol. 22Issue 7PreviewThere has been reported that the association between nodal spread and tumor size was disrupted in triple-negative breast cancer (TNBC) and it showed characteristically early relapse. The TNM (tumor–node–metastasis) staging system might not be equally effective as a prognostic indicator for all subtypes. The aim of our study was to evaluate the usefulness of the staging according to subtypes. Full-Text PDF Open Archive
Research Snippets
Journal: British Journal of Dermatology (2005)

British Journal of DermatologyVolume 153, Issue 4 p. vii-vii Research Snippets First published: 16 September 2005 https://doi.org/10.1111/j.1365-2133.2005.06943.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume153, Issue4October 2005Pages vii-vii RelatedInformation
Rapid fire ‐Clinical 1
Authors: Jpe Lassus, ; Tarvasmaki, ; Mebazaa, ; Sionis, ; Tolppanen, ; Metra, Di Somma, ; Kober, J Parissis, ; V-P Harjola, Ppilar Garcia-Gonzalez, ; De, La Espriella-Juan, ; Cozar-Santiago, ; Bochard-Villanueva, ; Chacon-Hernandez, ; Sanchez-Jurado, ; A Quesada-Dorador, ; Ferrer-Rebolleda, ; Ridocci-Soriano, E Simantirakis, Eeva Arkolaki, A Patrianakos, E Nakou, P Papakonstantinou, P Vardas
Journal: European Journal of Heart Failure (2014)
Inviting Patients to Read Doctors' Notes
Authors: Ying Y Zhao, Matthew A Weir, Michael Manno, Peter Cordy, Tara Gomes, Daniel G Hackam, David N Juurlink, Muhammad Mamdani, Louise Moist, Chirag R Parikh, J Michael Paterson, Ron Wald, Zhan Yao, Amit X Garg
Journal: Annals of Internal Medicine (2012)

Fibric acid derivatives (fibrates) have been shown to increase serum creatinine level in randomized trials.To assess renal outcomes in elderly adults within 90 days of a new fibrate prescription.Population-based cohort study.Ontario, Canada.Patients aged 66 years or older with a new outpatient prescription for a fibrate or ezetimibe (comparator drug) between January 2004 and December 2008.Hospitalization for an increase in serum creatinine level (primary outcome) and consultation with a nephrologist, receipt of dialysis for severe acute kidney injury, all-cause mortality, and increases in serum creatinine level (secondary outcomes). All outcomes were assessed within 90 days of a new prescription for ezetimibe or a fibrate.Compared with ezetimibe users (n = 61,831), fibrate users (n = 19,072) were more likely to be hospitalized for an increase in serum creatinine level (adjusted odds ratio, 2.4 [95% CI, 1.7 to 3.3]) and were more likely to consult a nephrologist (absolute risk difference, 0.15% [CI, 0.01% to 0.29%]; adjusted odds ratio, 1.3 [CI, 1.0 to 1.6]). There were no differences between groups in the risk for all-cause mortality or receiving dialysis for severe acute kidney injury. In a subpopulation of 1110 patients (fibrates, n = 220; ezetimibe, n = 890), 9.1% of fibrate users and 0.3% of ezetimibe users had an increase in serum creatinine level of 50% or more (absolute difference, 8.8% [CI, 4.5% to 13.1%]; odds ratio, 29.6 [CI, 8.7 to 100.5]). Risks were greater among fibrate users with chronic kidney disease.Because hospitalizations for an increase in serum creatinine level were underestimated, absolute differences may be misleading. Most patients (91%) were prescribed fenofibrate. Serum creatinine levels were measured as part of routine care and were not available for everyone or at predefined times.New fibrate use in elderly adults was associated with an increase in serum creatinine level and a small 90-day absolute increase in hospitalizations and nephrologist consultations. There was no detectable effect on dialysis for severe acute kidney injury or on mortality. The mechanism and clinical significance of the increase in serum creatinine level with fibrates is unclear.Ontario Ministry of Health and Long-Term Care Drug Innovation Fund.
Highlights
Journal: JAMA Surgery (2017)

Do rude and disrespectful behaviors identifi ed through patient complaints predict postoperative complications?Cooper and colleagues reviewed unsolicited patient complaints for surgeons operating on 32 125 patients in the National Surgical Quality Improvement Program from 7 academic sites.Patients whose surgeons had more patient complaints in the previous 2 years had a signifi cantly increased risk of having postoperative surgical and medical complications.
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
Authors: R. Stupp
Journal: Journal of Clinical Oncology (2002)

PURPOSE: Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM). This phase II study was performed to determine the safety, tolerability, and efficacy of concomitant radiation plus temozolomide therapy followed by adjuvant temozolomide therapy in patients with newly diagnosed GBM. PATIENTS AND METHODS: Sixty-four patients were enrolled onto this open-label, phase II trial. Temozolomide (75 mg/m2/d × 7 d/wk for 6 weeks) was administered orally concomitant with fractionated radiotherapy (60 Gy total dose: 2 Gy × 5 d/wk for 6 weeks) followed by temozolomide monotherapy (200 mg/m2/d × 5 days, every 28 days for six cycles). The primary end points were safety and tolerability, and the secondary end point was overall survival. RESULTS: Concomitant radiation plus temozolomide therapy was safe and well tolerated. Nonhematologic toxicities were rare and mild to moderate in severity. During the concomitant treatment phase, grade 3 or 4 neutropenia, thrombocytopenia, or both were observed in 6% of patients, including two severe infections with Pneumocystis carinii. During adjuvant temozolomide, 2% and 6% of cycles were associated with grade 3 and 4 neutropenia or thrombocytopenia, respectively. Median survival was 16 months, and the 1- and 2-year survival rates were 58% and 31%, respectively. Patients younger than 50 years old and patients who underwent debulking surgery had the best survival outcome. CONCLUSION: Continuous daily temozolomide and concomitant radiation is safe. This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma. Further investigation is warranted, and a randomized trial is ongoing.
Masthead: (Adv. Healthcare Mater. 9/2018)
Journal: Advanced Healthcare Materials (2018)

Citizenship: Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups.Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.
Book Review The Medical Department of the United States Army in the World War . Volume X. Neuropsychiatry. In the United States, by Col. Pearce Bailey, M.C., Lieut. Col. Frankwood E. Williams, M.C., Sergt. Paul O. Komora, M.D. In the American Expeditionary Forces, by Col. Thomas W. Salmon, M.C., Sergt. Norman Fenton, M.D. Prepared under the Direction of Maj. Gen. M. W. Ireland, the Surgeon General. Washington: U. S. Government Printing Office: 1929.
Journal: New England Journal of Medicine (1929)
Athletics in Education.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brigatinib Approved, but Treatment Role Uncertain
Journal: Cancer Discovery (2017)

The FDA has approved the ALK inhibitor brigatinib for patients with metastatic non-small cell lung cancer who cannot take crizotinib or whose disease worsened despite its use. The decision was based upon results of a phase II study that assessed two drug doses, with overall response rates of 45% and 56% respectively. The drug's effect on overall survival remains unclear, as does the optimal sequence of brigatinib and the three other ALK inhibitors.
Anti-Inflammatory Drugs in Asthma.
Authors: R Cameron, J Kolbe, M Wilsher, N Lambie
Journal: Thorax (2000)

The spectrum of nitrofurantoin lung injury continues to widen.The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin.Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced.The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP.We suggest that the previous classification of nitrofurantoin induced lung injury into "acute" and "chronic" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged.
Abstract 911: UCSC Xena for cancer genomics visualization and interpretation
Authors: Mary Goldman, Brian Craft, Jingchun Zhu, David Haussler
Journal: Cancer Research (2019)

Abstract UCSC Xena (http://xena.ucsc.edu/) is a web-based visual integration and exploration tool for multi-omic data and associated clinical and phenotypic annotations. Our unique Visual Spreadsheet shows multiple data types side-by-side enabling discovery of correlations across and within genes and genomic regions. We offer dynamic Kaplan-Meier survival analysis, powerful filtering and subgrouping, charts, statistical analyses, genomic signatures, comparative transcript views, and bookmarks. We link out to the UCSC Genome Browser, giving users additional genomic context for any gene or coordinate, as well as MuPIT/CRAVAT and TumorMap, to give users complementary views of the same data. Xena showcases seminal cancer genomics datasets from TCGA, the Pan-Cancer Atlas, PCAWG, GDC, GTEx, ICGC, and more; a total of more than 1500 datasets across 50 cancer types. We support virtually any type of functional genomics data. In addition to the commonly available SNPs, INDELs, copy number variation, and gene expression datasets, we support DNA methylation, exon-, transcript-, miRNA-, lncRNA-expression and structural variants. We also support clinical data such as phenotypes, subtype classifications and biomarkers. A recompute of TCGA, TARGET and GTEx datasets through the same bioinformatics pipeline allows users to compare expression between tumor and normal tissues. All of our data is available for download via our python API or through AWS S3 buckets. A researcher can host their own data securely via private hubs running on a laptop or behind a firewall, with visual and analytical integration occurring only within the Xena Browser. The lightweight Xena Data Hubs are straightforward to install on Windows, Mac and Linux. Loading data is easy using either our application or command line interface. Our newest features include: * a new, more intuitive wizard to load your data into a local Hub * URL bookmarks to save interactive views for yourself or to share with collaborators * genomic signatures: dynamically build as a weighted sum over a set of genes * hierarchically cluster a list of genes, regulons or probes * upper vs lower quartile in a KM plot Citation Format: Mary Goldman, Brian Craft, Jingchun Zhu, David Haussler. UCSC Xena for cancer genomics visualization and interpretation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 911.
Buprenorphine Implants (Probuphine) for Opioid Dependence
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Acquired immunodeficiency syndrome among patients with hemophilia
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clioquinol, Iodochlorhydroxyquin
Authors: STUART C. SCHEER
Journal: Annals of Internal Medicine (1973)

Letters, Comments, and Corrections1 February 1973Clioquinol, IodochlorhydroxyquinSTUART C. SCHEER, M.D.STUART C. SCHEER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-78-2-309_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: With reference to the excellent editorial on subacute myelo-optico-neuropathy (SMON) by Dr. Erland Nelson (Ann Intern Med 77:468-470, 1972), I wish to point out that clioquinol (5-chloro-7-iodo-8-quinolinol), the drug linked in Japan with SMON, probably sounds to most American physicians like some obscure chemical.For those unfamiliar with the name clioquinol, which is a proposed, international nonproprietary name, the generic name used in the United States is lodochlorhydroxyquin, which is marketed under the trade name Entero-Vioform® (Ciba).Iodochlorhydroxyquin has been and still is commonly prescribed by physicians for the prevention and treatment of travelers' diarrhea. The drug... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: STUART C. SCHEER, M.D.Affiliations: Regional Medical Officer American Embassy Addis Ababa Ethiopia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1973Volume 78, Issue 2Page: 309-309KeywordsDiarrheaDrugs ePublished: 1 December 2008 Issue Published: 1 February 1973 PDF downloadLoading ...
Miscellany
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Air Embolism During Neurosurgery
Authors: John D. Michenfelder
Journal: JAMA (1969)

During a seven-year period, 2,002 neurosurgical procedures were done with the patients in the sitting position. Forty episodes of air embolism were recognized in 32 of these patients and all but one episode occurred during surgery on the posterior cranial fossa. In 18 patients, a catheter had been previously placed in the right atrium (21 episodes) or superior vena cava (two episodes). In all of these, the diagnosis was confirmed by the aspiration of volumes of air varying from 2 to 400 ml. During eight of the episodes, volumes exceeding 10 ml of air were aspirated. This experience supports a recommendation for placement of a catheter in the right atrium prior to surgical procedures likely to be complicated by air embolism.
Practice Management Workshops for Residents
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal